Sanofi

Cadenza Bio, Inc. Appoints Michael A. Panzara, MD, MPH, to its Board of Directors

Retrieved on: 
Thursday, April 4, 2024
Neurology, Sanofi, Alemtuzumab, Myelin, Public health, Growth, Massachusetts General Hospital, Multiple sclerosis, University, Patient, Research, Inflammation, Biology, Interferon beta-1a, MPH, Brigham and Women's Hospital, DSM-IV codes, Hospital, Drug development, Natalizumab, Rheumatology, Pharmaceutical industry

He also serves on the board of directors of Athira Pharma, Inc., a neurology-focused clinical-stage biopharmaceutical company.

Key Points: 
  • He also serves on the board of directors of Athira Pharma, Inc., a neurology-focused clinical-stage biopharmaceutical company.
  • "We are delighted to welcome Dr. Panzara to our board of directors," said Dr. Carol Curtis, chief executive officer of Cadenza Bio.
  • "His extensive experience in developing therapies for MS and other neurological disorders aligns perfectly with our mission at Cadenza Bio.
  • "I look forward to joining the board of directors at Cadenza Bio at such an exciting time in the growth of the company," said Dr. Panzara.

BLACK HEALTH MATTERS TO HOST FREE SPRING HEALTH SUMMIT AND EXPO IN WASHINGTON, D.C.

Retrieved on: 
Wednesday, April 3, 2024
Kidney, Glucose, LDL, Exercise, Hepatitis C, Jabari, Black, BMS, National Pan-Hellenic Council, Patient, Vertex, Lunch, PSA, Legislation, Education, Gallaudet University, Omega Psi Phi, Incontinence, Johnson & Johnson, Cholesterol, WRC-TV, Triglyceride, Hypertension, Sanofi, Doctor of Pharmacy, Leukemia, Memory, Food, HDL, Phi Beta Sigma, Health, COVID-19 vaccine, Conference, BHM, COVID-19, All My Children, Howard University Hospital, Breakfast, Kidney disease, Diet, Guru, Sibley Memorial Hospital, Pharmaceutical industry

WASHINGTON, April 3, 2024 /PRNewswire/ -- Black Health Matters (BHM) – a leading nonprofit health advocacy organization that provides health and wellness information to the Black community – will host its annual Black Health Matters Spring Health Summit and Expo in Washington, D.C. on Saturday, April 13. As part of the award-winning health summit series, the free, one-day event will be held at the Kellogg Conference Hotel at Gallaudet University at 800 Florida Avenue, N.E., Washington, DC 20002 and includes celebrity hosts, medical professionals, health screenings, prizes, breakfast, and lunch. The event is open to the public and will begin at 8:30 a.m. with breakfast and conclude at 3:30 p.m.

Key Points: 
  • Popular health-focused event to feature free screenings, conversations with experts and celebrities
    WASHINGTON, April 3, 2024 /PRNewswire/ -- Black Health Matters (BHM) – a leading nonprofit health advocacy organization that provides health and wellness information to the Black community – will host its annual Black Health Matters Spring Health Summit and Expo in Washington, D.C. on Saturday, April 13.
  • After over a decade of hosting the popular health-focused summits, this will be the first in Washington, D.C. for Black Health Matters.
  • The Black Health Matters Spring Summit & Expo is sponsored by leading health organizations including Sanofi|Regeneron, Johnson & Johnson Health Care Systems, Johnson & Johnson Innovative Medicine, Research Includes Me, BMS, Sanofi, argenx, Vertex and CISCRP.
  • Notable partners are Howard University Hospital; DC Department of Health Care Finance; Precision Wellness; and American Association of Kidney Patients.

Jay Appel, Chief Innovation & Growth Officer at The Bloc, Inducted into DTC Perspectives' 2024 Hall of Fame for Transformative Impact in Healthcare Marketing

Retrieved on: 
Tuesday, April 2, 2024
Editorial, Conference, Health, Growth, Communication, Digital, Patient, Digitas Health, Bristol Myers Squibb, Sanofi, DTC, Marketing, Advertising, Security (finance)

NEW YORK, April 2, 2024 /PRNewswire/ -- The Bloc , a renowned global health-native agency, is proud to announce that Jay Appel, Chief Innovation & Growth Officer, will be inducted into the DTC Hall of Fame for the year 2024.

Key Points: 
  • NEW YORK, April 2, 2024 /PRNewswire/ -- The Bloc , a renowned global health-native agency, is proud to announce that Jay Appel, Chief Innovation & Growth Officer, will be inducted into the DTC Hall of Fame for the year 2024.
  • This is an honor presented by DTC Perspectives, the leading forum for direct-to-consumer (DTC) advertising thought leaders.
  • "It is important to recognize those individuals who have shaped DTC advertising and significantly contributed to the communication of important healthcare information directly to patients."
  • His induction into the DTC Hall of Fame is a testament to the remarkable impact he has made," said Jennifer Matthews, President and CEO of The Bloc.

Global Smart Insulin Pens Market 10 Year Forecast Report 2024-2034 - A USD 2.30 Billion Market by 2034 with a 10% CAGR During 2024-2034

Retrieved on: 
Thursday, March 28, 2024
Diabetes, CGM, Sanofi, Eli Lilly, Prevalence, Dexcom, Data analysis, Incidence, Partnership, Insulin, Patient, Continuous glucose monitor, Prescription, Novo Nordisk, Investment, Research report, USD, Pharmaceutical industry

DUBLIN, March 28, 2024 /PRNewswire/ -- The "Global Smart Insulin Pens Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 28, 2024 /PRNewswire/ -- The "Global Smart Insulin Pens Market" report has been added to ResearchAndMarkets.com's offering.
  • The global smart insulin pens market accounted for USD 0.769 billion in 2023 and is expected to reach at USD 2.30 billion by 2034 with a CAGR of 10.47% during the forecast period 2024-2034.
  • Diabetes, particularly types 1 and 2, is becoming more common, which has increased demand for cutting-edge and effective insulin administration systems like smart insulin pens.
  • Advanced technology like Bluetooth connectivity, smartphone applications, and electronic dose-tracking features are all integrated into smart insulin pens.

DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results

Retrieved on: 
Thursday, March 28, 2024
Nexus, DTS, Sanofi, Growth, Partnership, Diabetes, Webcast, Ratio, Research, Acquisition, Diabetes Technology Society, Prediabetes, Traction, Depreciation, GAAP, Hypertension, Total, Medicine, Marketing, Video game

NEW YORK, March 28, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the fourth quarter 2023 and the full year 2023 and provided a corporate and commercial update.

Key Points: 
  • NEW YORK, March 28, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the fourth quarter 2023 and the full year 2023 and provided a corporate and commercial update.
  • Gross profit as a percentage of revenues decreased to 3.7% in the fourth quarter of 2023, from 40.1% in the fourth quarter of 2022, and 17.3% in the third quarter of 2023.
  • Total operating expenses for the fourth quarter ended December 31, 2023, were $14.3 million compared with $11.7 million for the fourth quarter ended December 31, 2022, and $16.1 million for the third quarter of 2023, an increase of $2.6 million, or 22.2%, compared to the fourth quarter of 2022, and a decrease of $1.8 million, or 11.2%, compared to the third quarter of 2023.
  • Total operating expenses excluding stock-based compensation, acquisition expenses and depreciation for the fourth quarter of 2023 were $9.9 million compared to $10 million for the fourth quarter of 2022, and $10.9 million for the third quarter of 2023.

ReportLinker Reveals Key Insights About Players and Coverage in Latest Combination Vaccine Market Analysis

Retrieved on: 
Tuesday, March 26, 2024
Intelligence, AP, Sanofi, Vaccine, NLP, Growth, Natural language processing, Immunization, Interview, Vaccination

This recent comprehensive study analyzes global volumes and utilization trends for aP combination vaccines, including hexavalent and pentavalent vaccines, and confirms Sanofi's leadership in the global pediatric combination vaccine market.

Key Points: 
  • This recent comprehensive study analyzes global volumes and utilization trends for aP combination vaccines, including hexavalent and pentavalent vaccines, and confirms Sanofi's leadership in the global pediatric combination vaccine market.
  • The study reveals a notable rebound in immunization rates, with DTP3 coverage rising to 84% in 2022, and delves into global trends in the utilization of aP-based hexavalent and pentavalent combination vaccines, highlighting significant market dynamics and leadership.
  • Geographically, Europe is noted for its significant share of the aP-based combination vaccines market, especially in the hexavalent and pentavalent categories.
  • This regional analysis, along with a detailed breakdown of vaccine usage in top countries, offers a clear view of global vaccination strategies and their impact.

ReportLinker Reveals Key Insights About Players and Coverage in Latest Combination Vaccine Market Analysis

Retrieved on: 
Tuesday, March 26, 2024
Intelligence, AP, Sanofi, Vaccine, NLP, Growth, Natural language processing, Immunization, Interview, Vaccination

This recent comprehensive study analyzes global volumes and utilization trends for aP combination vaccines, including hexavalent and pentavalent vaccines, and confirms Sanofi's leadership in the global pediatric combination vaccine market.

Key Points: 
  • This recent comprehensive study analyzes global volumes and utilization trends for aP combination vaccines, including hexavalent and pentavalent vaccines, and confirms Sanofi's leadership in the global pediatric combination vaccine market.
  • The study reveals a notable rebound in immunization rates, with DTP3 coverage rising to 84% in 2022, and delves into global trends in the utilization of aP-based hexavalent and pentavalent combination vaccines, highlighting significant market dynamics and leadership.
  • Geographically, Europe is noted for its significant share of the aP-based combination vaccines market, especially in the hexavalent and pentavalent categories.
  • This regional analysis, along with a detailed breakdown of vaccine usage in top countries, offers a clear view of global vaccination strategies and their impact.

MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor

Retrieved on: 
Thursday, March 21, 2024
Discovery, Research, Depression, Epilepsy, MIRA, Development, Shire (pharmaceutical company), Stroke, Litoxetine, IND, VPA, Sanofi, Clinical trial, Research and development, Investigational New Drug, Drug development, Marketing, Pharmaceutical industry

MIAMI, March 21, 2024 /PRNewswire/ -- MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company focused on the development of novel treatments for neurologic and neuropsychiatric disorders, proudly announces the appointment of distinguished pharmaceutical executive Dr. Itzchak Angel as its new Chief Scientific Advisor.

Key Points: 
  • Dr. Angel brings over 40 years of preclinical, clinical and regulatory acumen to MIRA.
  • He has significantly contributed to the research, development and regulatory approval of groundbreaking medications over his remarkable career.
  • Additionally, his activities contributed to the development and marketing of Mizollen (mizolastine), Xatral (alfuzosin) and Ambien (zolpidem).
  • "We are truly honored to have Dr. Angel on our team," stated Erez Aminov, Chairman & CEO of MIRA.

Advances in Digitalization Presented at the 10th Annual Genedata Biopharma Partner Symposium

Retrieved on: 
Thursday, March 21, 2024
AbbVie, Peptide, ChromeOS, Automation, Sanofi, Organization, Canadian Aviation Regulations, AstraZeneca, Novo Nordisk, MAM, Novartis, GSK, Boehringer Ingelheim, UCB, Vivisection, Roche, NGS, RNA, Knowledge, Merck, Hyphen, Spacecraft, Janssen, Daiichi Sankyo, Digitization, Novozymes, Fine chemical

BASEL, Switzerland, March 21, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful conclusion of the 10th Annual Genedata Biopharma Partner Symposium, held over 2 days from March 6–7, 2024 in Basel, Switzerland. This year's event marked the tenth year of bringing together Genedata customers to share best practices and demonstrate how they increase efficiency and productivity across entire organizations by leveraging the Genedata Biopharma Platform.

Key Points: 
  • BASEL, Switzerland, March 21, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful conclusion of the 10th Annual Genedata Biopharma Partner Symposium, held over 2 days from March 6–7, 2024 in Basel, Switzerland.
  • The Genedata Biopharma Partner Symposium has firmly established itself as a community platform to exchange pioneering work in digitalizing biopharma R&D and establishing best practices based on the Genedata software platform.
  • "The Genedata Biopharma Partner Symposium has firmly established itself as a community platform to exchange pioneering work in digitalizing biopharma R&D and establishing best practices based on the Genedata software platform.
  • The record participation this year underscores the leading position of the Genedata Biopharma Platform within the biopharma industry," said Othmar Pfannes, Ph.D., CEO of Genedata.

Bioforum Expands Leadership Team with Appointment of Michael Goedde as President

Retrieved on: 
Tuesday, March 19, 2024
Automation, ChromeOS, Sanofi, Development, MedImmune, NESS, ICON PLC, Database, CLZ, Goedde, Trustee, CNS, ICON, Biostatistics, Research, Hoechst AG, Society, SDTM, BioGRID, Human Genome Sciences, Parexel, Nursing

NESS ZIONA, Israel, March 19, 2024 /PRNewswire/ -- Bioforum, the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and solutions to the global clinical trials industry, today announced the appointment of Michael Goedde as its President. A clinical data management expert whose career in the life sciences industry spans over three decades, Goedde will drive the development and execution of Bioforum's global growth and innovation strategy. 

Key Points: 
  • A clinical data management expert whose career in the life sciences industry spans over three decades, Goedde will drive the development and execution of Bioforum's global growth and innovation strategy.
  • "As we expand our presence in North America and around the world, I'm delighted to welcome Michael to the Bioforum family and confident that his leadership will be invaluable in driving our long-term growth and success."
  • Prior to ICON, Goedde spent four years at Parexel in roles of increasing responsibility, most recently as Vice President of Global Data Operations.
  • He holds a bachelor's degree in computer science from Computer Lern Zentrum (CLZ) Hoechst AG in Frankfurt, Germany.